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Abstract
Changes of mean platelet volume (MPV) and platelet count (PC) could be a marker or
a predictor of acute stroke (AS). We conducted a systematic review and meta-analysis of the
published literature on the reporting of MPV and PC in AS. Studies were included in accor-
dance with Patient Population or Problem, Intervention, Comparison, Outcomes, and Setting
framework. The PRISMA strategy was used to report findings. Risk of bias was assessed with the
Newcastle-Ottawa Scale. We included 34 eligible articles retrieved from the literature. PC was
significantly lower in AS patients [standardized mean difference (SMD) = − 0.30, (95% CI: − 0.49
to − 0.11), N = 2492, P = .002] compared with controls (N = 3615). The MPV was significantly
higher [SMD = 0.52 (95% CI: 0.28–0.76), N = 2739, P < .001] compared with controls (N = 3810).
Subgroup analyses showed significantly lower PC in both ischemic stroke (Difference SMD =
−0.18, 95% CI: −0.35–0.01) and hemorrhagic stroke (−0.94, −1.62 to −0.25), but only samples by
citrate anticoagulant showed significantly lower result for patients compared to controls
(−0.36, −0.68 to −0.04). Ischemic stroke patients had higher MPV (0.57, 0.31–0.83), and samples
by Ethylenediaminetetraacetic acid (EDTA) anticoagulant showed significantly higher result for
patients compared to controls (0.86, 0.55–1.17). PC and MPV appeared to be significantly
different between patients with AS and control populations. MPV was significantly higher in
ischemic stroke and PC was significantly lower in both ischemic and hemorrhagic strokes.
These characteristics might be related to AS and associated with it. It is advisable to pay
attention to elapsed time between phlebotomy and hematology analysis, anticoagulant and
hemocytometer types in AS.
Systematic review registration: This meta-analysis is registered on the International Prospective
Register of Systematic Reviews (PROSPERO) under registration number CRD42017067864 (https://
www.crd.york.ac.uk/prospero/display_record.php?RecordID=67864).
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Introduction
Incidence of stroke in Europe is 95 to 290/100,000 per year and it is
the fourth cause of death in the United States [1,2]. The important
role of platelets in the pathogenesis of the atherothrombosis and
ischemic stroke has been documented [3,4]. Mean platelet volume
(MPV) is regarded as a marker of platelet turnover [5]. More imma-
ture, thereby larger platelets usually contain more granules, thus
releasing more chemokines promoting further platelet aggregation
as well as activation. Elevated MPV simultaneously with the elevated
PC increases the risk of thrombosis [6]. Significant increased MPV
in patients with deep vein thrombosis and isolated elevated PC in
patients with pulmonary embolism has been revealed [7].
Modification of platelet function and consequently
a hypercoagulable state has been suggested in patients with both
ischemic and hemorrhagic strokes [8]. It has been shown that PC
and MPV are independent predictors for poor outcome in primary
intracerebral hemorrhage (PICH) [9]. There has also been a body
of interest for PC and MPV in stroke patients. However, these
studies have yielded inconsistent findings. Some groups reported
that patients with AS had significantly increased MPV or PC
compared with controls [10,11], whereas other studies found
decreased MPV or PC values in AS patients [12,13].
Additionally, some studies have observed no association between
these parameters and AS [14,15]. Taking these inconsistent find-
ings into consideration, we undertook a meta-analysis to investi-
gate the association between MPV, PC, and AS.
Methods
Protocol and Registration
The present systematic review and meta-analysis was conducted,
according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [16] and was
demonstrated according to the MOOSE (Meta-analysis of
Observational Studies in Epidemiology) statement [17]. The
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systematic review and meta-analysis protocol was registered with
the PROSPERO database at: https://www.crd.york.ac.uk/pros-
pero/display_record.php?RecordID=67864
Search Strategy and Study Selection
Eligibility criteria were in accordance with the Patient Population
or Problem, Intervention, Comparison, Outcomes, and Setting
inclusion criteria [16]. We modified the PICOS excluding I,
where I represents the Interventions, since no interventional stu-
dies were included. Studies were included if they (1) studied adult
individuals, (2) included a control group, (3) involved the diag-
nosis or evaluation of acute stroke, (4) included the detailed data
about platelet indices in both patient and control groups, and (5)
were case-control or cross-sectional studies. There was no lan-
guage, country or time restriction. We excluded reviews, editor-
ials, commentaries, abstracts, and conference proceedings.
Cerebrovascular events and acute stroke were assessed in this
study as the outcomes.
The basis for our analysis was the comprehensive search for
the relevant studies published in Medline, EBSCOhost, Web of
Science, ScienceDirect, Google Scholar and Scopus from incep-
tion to July 2017 (Supplementary file 1). The last search was
performed on August 2019 and we included published studies.
Google Scholar was searched by Harzing’s Publish or Perish
program (Harzing, A.W., 2007, Publish or Perish, available from
https://harzing.com/resources/publish-or-perish). The keywords
used for systematic searches were as follows: platelet indices,
platelet parameters, mean platelet volume, platelet count, stroke,
and cerebrovascular disease.
Data Extraction
Two reviewers independently extracted the Data (AHS and FS) by
using a standard form and cross-checked. Discrepancies were
resolved by consensus or through discussion with the third author
(ZC). We used bibliographies of the retrieved articles for other
relevant studies. All data were prospectively collected.
After the first search, reviews remained on the list to collect
appropriate references. At the second step, we removed all
reviews from the list of accepted publications.
We used the Newcastle-Ottawa Scale (NOS) to evaluate the
quality of the eligible studies [18]. NOS includes a selection of the
study population domain, comparability of the groups’ domain, and
ascertainment of the outcome domain. Articles identified as high
quality withNOS scores 6–9, whereas scores of 0–5were considered
to indicate poor quality. In those studies that provided only median
with range or interquartile range values, mean and standard devia-
tion were calculated according to Wen et al. [19].
Data Synthesis and Statistical Analysis
This study was conducted by following the guidelines of
Viechtbauer and Huzsvai and Balogh [20,21]. The meta-analysis
involved between-study variances and also covariates for limiting
publication biases. Standardized mean differences (SMDs) were
estimated for MPV and PC within each study. We also conducted
subgroup analysis by a random-effect (RE) meta-analysis for the
assessment of heterogeneity using the type of anticoagulant (EDTA
or citrate), type of analyzer (Sysmex or Coulter), and type of
infarction [ischemic stroke (IS) or PICH] as covariates. Then,
a mixed-effect (ME) meta-regression was performed using the type
of infarction and type of analytes as themoderator variables.We also
performed an outlier detection for MPV regarding storage time and
type of analyte. Heterogeneity was quantified using the I2 statistics
across studies. Publication bias was assessed through graphical
Begg’s funnel plots and Egger’s regression symmetry statistical
tests [22]. We performed both adjusted and unadjusted parametric
bootstrap sampling with 10,000 replicates of the original data using
the normal distribution. All analyses were performed by using the
statistical software R 3.3.2 and its metafor package (https://cran.
r-project.org).
Results
A flowchart diagram of the progression of papers through the
review process is shown in Figure 1. A total of 6812 studies were
identified. Supplementary Table I shows search protocols and
their details for each database separately. A total of 2746 dupli-
cates (40.3%) were excluded, and 3810 (55.9%) articles were
removed after reviewing the title and/or abstract. The remaining
256 articles were assessed for eligibility criteria by screening their
titles and abstracts. Following detailed evaluation, 39 studies were
selected for qualitative assessment. We corresponded with authors
for five studies, but data were not available. Therefore, 34 articles
were included in the meta-analysis [10–15,23-50]. Three studies
were carried out in the United States, 12 in Europe, ten in Asia,
one in Africa, and eight studies were intercontinental. Patient
populations ranged from 12 to 384 individuals.
Most of the included studies were about acute ischemic stroke
(82%). Thirteen studies did not report the type of analysate (38%),
and almost the same number of studies failed to report the type of
hematology automated analyzer (41%) (Table I and more details
at Supplementary Table II). Elapse time between phlebotomy and
measurement of 20.5% of the studies was more than 2 h. Most of
the studies missed to report stroke-related comorbidities (Table I).
The Dersimonian-Laird estimator was used to estimate ME and
RE models for PC MPV (Supplementary Table III). Funnel plot
indicates publication biases in the RE model, especially for MPV,
but the ME model for both variables does not contain publication
biases (Supplementary Figure 1). We applied the weighted regres-
sion model with multiplicative dispersion and t-values were calcu-
lated. Egger’s test provided evidence for publication biases in RE
model only for MPV (P < .001), but in case of PC t-statistics show
stronger symmetry for the mixed effects model (Supplementary
Table IV). There were no false high MPV values during our outlier
detection procedure. Bootstrap sampling was used to validate both
RE andMEmodels and to avoid the overfitting of the models in case
of a low number of studies (Supplementary Table V).
PC
A total of 6107 participants were selected from 24 publications, of
which 2492 were assigned to the patient group and 3615 to the control
group. Three studies showed that patients with AS had higher PC than
controls [24,35,36]. Eleven studies demonstrated lower PC in the
patient group [12–14,23,25–27,30,32,35,43], and 11 studies found
no difference in PC between patients and controls (Table I,
Supplementary Table VI) [11,15,28,29,33,37,41,42,44,46,47]. One
study did not provide PC results. The mean PC for all publications
was 234 G/L (95% CI: 224–244) for patients and 248 G/L (95% CI
238–259) for controls. There was a marked residual heterogeneity by
ME model for PC [χ2 = 230.2; df = 27; I2 = 88.3% (95% CI:
80.0–93.1); P < .001]. The estimated pooled mean difference in PC
was 0.48 G/L [Z = 1.61; P = .107] regarding the ischemic stroke for
theMEmodel. It was−0.30 (Z =−3.15, 95% CI:− 0.49–−0.11, P=
.002) for the RE model without moderating effects (Figure 2).
MPV
Seventeen results of the 27 studies revealed that patients with stroke
had higher MPV than controls [10,12,25,27,28,34,35,39,41–43,
2 F. Sadeghi et al. Platelets, Early Online: 1–9
46-48,50]. Ten studies found no difference in MPV between patients
and controls [14,15,28,29,35,36,38,45,49], and two studies demon-
strated a higher MPV in the control group (Table I, Supplementary
Table VI) [13,40]. The mean MPV for all publications was 9.8 fL
(95% CI 9.4–10.1) for patients and 9.2 fL (95% CI, 8.8–9.6) for
controls. There was a marked residual heterogeneity by ME model
for MPV [χ2 = 333.5; df = 20; I2 = 94% (95% CI: 89–97); P < .001].
The estimated pooled mean difference in MPV was 0.86 (Z = 5.509;
P < .001) for the ME model regarding the type of analyte effect
(EDTA compared to Citrate). It was 0.52 fL (Z = 4.29, P < .001) for
RE model without moderating effects (Figure 3).
Subgroup Analysis
We also performed subgroup and sensitivity analyses according to
the type of infarction, type of analyzer and type of analyte for
MPV and PC to further evaluate the relationship between these
parameters. Twelve studies measured complete blood count in
120 min or less, and seven studies assessed blood samples after
120 min. We analyzed them in a separate subgroup. Out of 34
studies which were included in this meta-analysis, three of them
had divided their studies into different subgroups (Table I)
[28,29,35].
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In 23 studies about acute ischemic stroke, 2007 cases demon-
strated significantly lower PC compared to 3090 control indivi-
duals (SMD = −0.18; 95% CI: − 0.35 to −0.01, P < .001)
(Figure 4 panel A, Supplementary Table VII). Six studies about
PICH revealed more significant results with 485 patients by
comparison with 525 controls (SMD = −0.94; 95% CI: −1.62
to −0.25, P < .001) (Figure 4 panel B, Supplementary Table VII).
Citrated samples for PC measurement showed significantly higher
results in 100 patients compared with 173 controls (SMD =
−0.36; 95% CI: −0.68 to −0.04, P < .05).
MPV was significantly higher in 2444 patients who suffered
acute ischemic stroke compared to 3405 controls (SMD = 0.57;
95% CI: 0.31–0.83, P < .001) (Figure 4 panel C, Supplementary
Table VIII). MPV was lower in patients compared with controls
in case of acute hemorrhagic stroke, but this difference was not
significant (SMD = 0.07; 95% CI: −0.10–0.25, P > .05) (Figure 4
panel D, Supplementary Table VIII). MPV from EDTA-
anticoagulated samples was measured in 17 studies, and it was
significantly higher in 1974 cases compared to 3209 control
individuals (SMD = 0.86; 95% CI: 0.55–1.17, P < .001).
Citrated samples from 208 cases showed lower MPV compared
to 186 controls (SMD = −0.13; 95% CI: −0.69–0.42, P < .001).
Sysmex hematology analyzers in 14 studies with 2727 controls
measured significantly higher MPV in 1557 patients (SMD =
0.64; 95% CI: 0.28–1.01, P < .001). Coulter hematology analy-
zers in six studies with 432 patients measured significantly higher
MPV compared with 347 controls (SMD = 0.58; 95% CI: 0.08–-
1.08, P < .001) (Supplementary Table VIII). We also examined
MPV results in two subgroups of elapsed time more than 120 min
or less than/equal to 120 min. This is the time delay between
venipuncture and analysis (Supplementary Table VIII). Compared
to control group, MPV was significantly higher in both ≤120 min
and >120 min groups (SMD = 0.72; 95% CI: 0.36–1.08, P <
.001) and (SMD = 0.70; 95% CI: 0.08–1.32, P < .001),
respectively.
Discussion
We conducted a systematic review and meta-analysis of the lit-
erature to evaluate PC and MPV in patients with AS. To the best
of our knowledge, this is the first meta-analysis assessing results
of MPV and PC on AS while considering the type of stroke and
some pre-analytical factors.
Larger platelets are more metabolically and functionally
active, platelets with high MPV contain more glycogen, ADP,
ATP, and reacting more readily to stimulating agents [51]. Platelet
dysfunction is described to be associated with PICH [52].
Platelets also have a prominent role in thromboemboli formation
that may initiate the symptoms of stroke. Recent meta-analysis
showed elevated MPV in different pathological conditions
[53,54].
Hypertension, diabetes mellitus, dyslipidemia, coronary artery
disease, and smoking habits are among the most important med-
ical pre-conditions and stroke-related comorbidities. Several lines
of evidence from the literature suggest that a direct correlation
exists between MPV and these traditional cerebrovascular risk
factors [55–60]. MPV was significantly higher (0.65 fL) in indi-
viduals with coronary artery disease and patients with high MPV
had 17% higher chance of having cardiovascular events compared
to patients with low MPV [61]. Another meta-analysis concluded
that MPV was significantly higher in those with acute myocardial
infarction than those without acute myocardial infarction [62].
Figure 2. Forest plot of standard mean difference (SMD) for association between platelet count and occurrence of acute stroke.
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Figure 3. Forest plot of standard mean difference (SMD) for association between mean platelet volume and occurrence of acute stroke.
Figure 4. Subgroup analysis for A – platelet count in patients with acute ischemic stroke, or B – platelet count in patients with acute hemorrhagic
stroke; and C – mean platelet volume in patients with acute ischemic stroke, or D – mean platelet volume in patients with acute hemorrhagic stroke.
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In our study, significantly higher MPV was found in acute
ischemic stroke and PC was significantly decreased in both acute
ischemic and hemorrhagic strokes.
Some authors consider a possible use of MPV assessments as
a potential biomarker of AS or as a prognostic marker in patients
after AS [10,12]. An association of MPV with stroke is possibly
due to higher platelet activity, aggregation, and turnover in
patients with elevated MPV. It has been shown that increased
MPV is linked to more hemostatically active platelets with higher
avidity to aggregate [63]. Additionally, increased turnover of
platelets causes the release of young, more active and larger
platelets from bone marrow [64]. The estimated pooled mean
difference of MPV was 0.51 fL and significantly higher in
patients with AS than controls. Moreover, MPV was significantly
higher in patients than controls after adjustment for the type of
analyte or analyzer. It should be acknowledged that these differ-
ences are rather small in absolute terms. Therefore, they might
reflect some changes of specific characteristics of the platelet
population and may also show the presence of more reactive
platelets within the blood stream in this group of patients.
Since the normal lifespan of platelets is between 8 and 10
days, the contribution of the elevated MPV in a prothrombotic
state and an increased risk of stroke is likely to be present prior to
stroke onset. Platelet activation measured by the levels of CD62P
(P-selectin) and circulating monocyte-platelet complex was
increased in stroke patients [65]. On the other hand, the level of
reticulated platelets as a marker of platelet production was the
same as controls in stroke patient [66]. These results suggest the
presence of continuous stimulation for platelet activation without
excessive platelet production after stroke. Monitoring stroke
patients revealed constant elevated MPV results post-stroke,
even three to 6 months after the event [25,28]. Low number of
studies related to acute hemorrhagic stroke and hyporeactive
platelets, as determined by significantly decreased platelet aggre-
gation rates induced by ADP [67], could explain partly constant
level of MPV in acute hemorrhagic stroke. Lower PC in acute
ischemic stroke could be contributed to platelet consumption
during acute phase of stroke [13]. Decreased PC number in
patients with acute hemorrhagic stroke is difficult to explain.
Consumption of platelets to produce effective lower PC requires
significantly larger hemorrhage than that usually seen in non-
traumatic acute hemorrhagic stroke. Medications such as antiepi-
leptics, or antibiotics may have attributed to lower PC. It seems
that modification of PC as an acute phase reactant requires addi-
tional time than duration of AS.
Pre-analytical conditions of MPV assessment have a great
effect on the results of platelet size. If MPV would apply as
a risk factor AS, its measurement should be standardized. This
fact is not only important for laboratory, but also for clinicians.
Type of anticoagulant for blood samples has also a significant
effect on platelet parameters measured by conventional hematol-
ogy analyzers [68]. It has been demonstrated previously that the
addition of EDTA anticoagulant to the sample causes artificial
platelet swelling [69]. However, this modification could be partly
explained by the alterations of both platelet cell wall and the
membranes lining the canalicular system and the change of
phosphorylation patterns of platelet proteins by exposure to
EDTA [70,71]. Sixty-one percent of the studies included in this
meta-analysis applied EDTA as an anticoagulant and it shows
significantly higher MPV for patients. It is important to mention
that almost half of the studies failed to report the type of analyte
they used for their study. Type of anticoagulant for blood
samples could also modify substantially PC results [72].
This phenomenon can be manifested by small-scale platelet
micro-aggregate formation with the usage of the citrate antic-
oagulant [73]. Our results demonstrated that the estimated
pooled mean difference of PC was −0.30 G/L in total patients
compared to controls.
Hematology analyzers may differ in the method they incorpo-
rate for the measurement of the platelet parameters. These con-
stitute mostly impedance or optical methods, and neither of them
take into account the shape change of platelets [74]. As a result,
these methods do not agree with each other. Sample storage time
is another parameter which influences MPV [75]. Although not
all studies stated sample storage time in their investigation, MPV
was significantly higher than controls in both ≤120 min and >120
min groups. One possibility to increase the chance to harmonize
the reporting of MPV is standardizing the elapse time between
venipuncture and MPV measurement.
There are some limitations to this study. Several reasons may
account for inconsistent results on the association between MPV
and stroke in the literature. Pooled estimates demonstrated large
heterogeneity. This can be explained by vast differences in pre-
analytical factors and demographic characteristics of the studied
population. Most of the studies failed to mention these character-
istics and it could be a potential source of heterogeneity. Only
a limited number of studies evaluated the potential confounding
effects of the traditional cerebrovascular risk factors, and pre-
analytical factors were profoundly diverse among them.
Significant heterogeneity exists among some studies, and the
results should be interpreted cautiously. Different results could
be related to the time difference between the stroke and blood
tests, failure to report the type of analyte or type of analyzer.
False results could be obtained as blood samples remain in con-
tact with anticoagulant for a long time. The difference in the
analyte used to anticoagulant the samples or assay methods
might also partly contribute to the high heterogeneity among
the studies.
We recommend future studies design to include a set of
standard covariates and pre-analytical factors. This can be
achieved by implanting specific time frame to measure the sample
results, define the type of anticoagulant in sample tube and
specify method of measurement. Lack of thorough documentation
of patient-related pre-analytical factors leads to higher variability
among studies.
In conclusion, MPV as a part of a routine complete blood
count is easily accessible and could be a surrogate marker of
platelet turnover. The results of this study emphasize that platelets
play a role in the pathogenesis of stroke, PC and MPV appeared to
be significantly different from control populations. Acute
ischemic stroke demonstrated significantly higher MPV, nonethe-
less both acute ischemic and hemorrhagic strokes revealed sig-
nificantly lower PC. These features might be associated with AS
and related to its occurrence.
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